Medpace (MEDP) Q3 2026 earnings review
Medpace contract awards hit a record, while sales growth slows
Medpace, which runs clinical trials for drugmakers, won a record amount of new contract work even as its current revenue growth slowed down. Third-quarter revenue rose 9% to $716 million, while net profit jumped 24% because lower zero-margin pass-through bills lifted operating margins. The company raised its full-year profit outlook and held its revenue target, which by our math leaves fourth-quarter sales less than 1% above last year.
| Revenue | $716.0M +8.5% from a year ago |
|---|---|
| Net new business awards | $873.4M +10.6% from a year ago (1.22x revenue) |
| EBITDA margin | 24.0% +1.5 percentage points from a year ago |
| Full-year outlook | Profit raised revenue midpoint held at $2.845B (+12.4%) |
⚖️ Verdict: 🟢 Bullish
The story got better because strong contract wins pushed the backlog past $3.17 billion, breaking out of a six-quarter stall. Pass-through expenses also dropped below management's forecast after three quarters of running hot, lifting profit margins. One caution: the rate at which backlog turns into quarterly revenue has started to ease from its recent peak, and that slowdown is holding back fourth-quarter sales.
The question now is whether the growing contract stockpile can offset a normalizing backlog burn rate in 2027. If the burn rate settles near current levels, the recent jump in trial awards will drive a rebound; if it reverts toward the old 18% norm, revenue growth will stay in the low single digits. Management's 2027 outlook on the call or in February will settle it.
🐂 Bull Case
New Trial Awards Push Backlog Past $3.1 Billion
Medpace runs clinical trials for drug and medical device makers, so its future sales depend on signing new trial contracts. Net new business awards — the value of new contracts won minus cancellations — rose 10.6% from a year ago to $873.4 million, the company said.
- Net book-to-bill ratio (new awards divided by revenue): 1.22 by our math, up from 1.13 last quarter
- Ending backlog (contracted work not yet completed): $3.17 billion, up 5.6% from a year ago
- Quarterly backlog addition: $153 million added since June by our math
This matters because ending backlog had stayed between $2.85 billion and $3.03 billion for six straight quarters while revenue grew much faster. Adding $873.4 million in new awards pushed the contract stockpile above that range, though new trial awards typically take about a year to turn into recorded revenue.
What to watch: the portion of backlog expected to turn into revenue over the next 12 months, disclosed in the quarterly filing. A rise above last quarter's $1.96 billion would show that recent contract wins are ready to start generating sales.
Lower Pass-Through Costs Lift Operating Margins
In clinical trials, Medpace pays outside investigators and clinics and bills those out-of-pocket costs straight to clients without a markup. For three straight quarters those pass-through costs ran higher than finance chief Kevin Brady had planned, which weighed on profit margins.
In the third quarter, reimbursed out-of-pocket expenses dropped to 40.1% of revenue by our math, down 1.8 percentage points from a year ago and below the 41% to 42% range Brady had modeled. Direct service costs (mainly clinical staff pay) rose 0.4 percentage points to 28.6% of revenue, while selling and administrative overhead held near 7.2%. Because low-margin pass-through bills shrank as a share of the total, the EBITDA margin (profit before interest, tax, depreciation and amortization) expanded by 1.5 percentage points to 24.0%, and the clinical research group raised its full-year EBITDA outlook by $15 million at the middle of the range.
What to watch: fourth-quarter reimbursed out-of-pocket expenses as a share of revenue. Staying near 40% would confirm that fast-burning metabolic trials with heavy pass-through bills are giving way to higher-margin service work.
Positives this quarter didn't test
Four standing drivers from prior quarters could not be checked because the earnings release omits trial-mix details and call commentary.
- Trial cancellations: net awards hit $873.4 million, but management only comments on gross bookings and cancellation rates during the conference call.
- Cancer-trial mix recovery: the quarterly filing's therapeutic-area table will show whether oncology rose from 29% of trailing twelve-month revenue.
- Unbooked award pool (pre-backlog): chief executive August Troendle previously said awarded work not yet in backlog was growing faster than backlog; the call will test if that held.
- Small-biotech funding breadth: the call and filing will show whether smaller drug developers kept funding new trials.
🐻 Bear Case
Full-Year Plan Leaves Fourth-Quarter Sales Nearly Flat
Quarterly revenue equals the opening backlog multiplied by the backlog conversion rate — the share of contracted work turned into revenue during the three months. That burn rate climbed from about 18% in 2024 to 24.1% in the second quarter of 2026, and chief executive August Troendle has warned it should eventually fall back toward historical norms.
In the third quarter, the conversion rate ticked down to 23.8%, and revenue growth slowed to 8.5% from 17.2% in the prior quarter. Medpace narrowed its full-year revenue forecast while keeping the middle of the range at $2.845 billion. By our math, that full-year plan leaves fourth-quarter revenue at $715.1 million, up less than 1% from a year ago, and points to the backlog conversion rate easing further to 22.6%.
Even with record new contract awards this quarter, the four-quarter lag before awards enter revenue means slowing conversion and a tough comparison against last year's 32% fourth-quarter growth are bringing top-line expansion to a near halt.
What to watch: management's initial 2027 revenue outlook on the upcoming call or in February. A forecast for single-digit growth in 2027 would show that a falling backlog conversion rate is offsetting the rebound in new trial awards.
Risks this quarter didn't answer
Five standing risks from earlier quarters received no new numbers in the third-quarter earnings release.
- Metabolic trial roll-off and top-customer concentration: the quarterly filing will show whether metabolic revenue fell for a third straight quarter and whether the top five clients stayed at 31% of revenue.
- Small-biopharma client exposure: the filing's customer-tier table will show if clients with under $250 million in sales remained at 84% of revenue.
- Book-to-bill shareholder lawsuits: the filing's legal note will update the class action and derivative suit over past booking disclosures.
- President vacancy and related-party ties: the release names no successor to the president who retired in May, and the filing will disclose related-party revenue from CinRx.
- Withheld backlog figures: the release still omits gross bookings, cancellation dollars, and the size of the unbooked contract pool.
👓 Other Themes
Board Approves $1 Billion Buyback After Zero Purchases
After spending $294.7 million on buybacks in the second quarter, Medpace reported that "There were no share repurchases in the third quarter of 2026", which helped cash climb to $705.3 million. On October 20, the board canceled the expiring $527.0 million buyback plan and approved a new program under which the company is "authorized to repurchase up to $1.0 billion shares of common stock until December 31, 2028", though it "does not obligate the Company to acquire any minimum amount of common stock".
💲 Other KPIs
Advanced billings — cash payments collected from trial sponsors before Medpace performs the work — rose 15.3% from a year ago by our math, outpacing the 8.5% rise in revenue. The balance grew by $57.1 million from the second quarter, lifting cash flows and keeping net working capital negative.
Medpace generated $216.6 million in operating cash flow and spent $20.2 million on property and equipment in the third quarter by our math, leaving $196.4 million in free cash flow. That rose from $138.1 million in the second quarter on higher upfront customer billings, though it fell 16.6% from a year ago due to heavier capital spending.
Weighted average diluted shares fell 1.5% from 28.82 million a year ago and 0.6% from 28.55 million in the second quarter. Even with no shares bought back during the third quarter, the second quarter's $294.7 million repurchase reduced the share count enough to add 1.7 percentage points to per-share profit growth over net income growth.
🔮 Guidance
Unchanged at the middle of the range. Medpace narrowed the forecast by $30 million on each side, keeping the midpoint at $2.845 billion, or 12.4% annual growth. By our math, that leaves fourth-quarter revenue at $715.1 million, up 0.9% from a year ago against last year's 32% jump. Across four quarters, the midpoint moves have been $0, +$40 million, and $0.
Raised. The middle of the range moved up $15 million to $645.0 million, or 15.7% growth for the year by our math. That leaves fourth-quarter EBITDA at $170.1 million, up 6.2% from a year ago at a 23.8% margin, compared with 24.0% in the third quarter. It is the second straight raise after moves of $0, +$10 million, and +$15 million.
Raised. The clinical research provider lifted the middle of the range by $15 million to $519.0 million, or 15.0% growth for the year by our math, helped by higher operating profit and $1.8 million more in expected net interest income. By our math, that leaves fourth-quarter net income at $136.3 million, up 0.9% from a year ago. Prior midpoint moves were $0, +$5 million, and +$15 million.
Raised. The middle of the range rose $0.55 to $18.15 per share, or 18.8% annual growth by our math, assuming 28.6 million diluted shares and no fourth-quarter buybacks. By our math, the plan leaves fourth-quarter profit at $4.78 per share, up 2.2% from a year ago. Across four quarters, the midpoint moves have been $0, +$0.51, and +$0.55.
❓ Key Questions
What drove the drop in pass-through expenses?
Reimbursed out-of-pocket costs fell to 40.1% of revenue, below the 41% to 42% range management modeled for the second half. Did large metabolic trials wind down faster than planned, or did trial activity shift toward service work?
What are the initial growth expectations for 2027?
Finance chief Kevin Brady said last quarter that management might give initial color on 2027 during the third-quarter call. With fourth-quarter revenue growth implied near 1% by our math, how fast can revenue grow in 2027?
How did gross bookings and cancellations behave?
Net new business awards reached $873.4 million in the third quarter. How much of that came from higher gross contract awards versus low trial cancellations, and what is the current dollar size of the unbooked award pool?
Why pause buybacks before authorizing $1 billion more?
Medpace bought no shares in the third quarter while holding $705.3 million in cash, then replaced its remaining $527 million authorization with a $1.0 billion program through 2028. What kept management on the sidelines during the quarter?